The one real success in targeted therapy, small molecule tyrosine kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) [81], is contingent upon the target kinase (ABL1) being the founder lesion in every cell and the clones having minimal genetic diversity. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.